SCHEMBL5058581

SCHEMBL5058581

CC(C)c1cc(NC(=O)Nc2cc(Oc3nccc(-c4cnn(C)c4)n3)ccc2F)n(-c2ccc(F)c(C#N)c2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 5/20 0.39
CSF1R P07333 5/20 0.37
PDGFRA P16234 4/20 0.37
BRAF P15056 6/20 0.36
KCNJ6 P48051 1/20 0.36
KCNJ5 P48544 1/20 0.36
KCNJ3 P48549 1/20 0.36
KDR P35968 4/20 0.36
MAPK14 Q16539 4/20 0.35
KIT P10721 2/20 0.35
PDGFRB P09619 2/20 0.35
MET P08581 3/20 0.35
FLT3 P36888 2/20 0.35
HCK P08631 2/20 0.35
SRC P12931 2/20 0.35
PLK4 O00444 1/20 0.35
ACOX3 O15254 1/20 0.35
MAP3K7 O43318 1/20 0.35
DYRK3 O43781 1/20 0.35
JAK2 O60674 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3133744 0.95 AXL (0.38) AXLCSF1RPDGFRABRAFKCNJ6
SCHEMBL11889168 0.93 AXL (0.39) AXLCSF1RPDGFRABRAFKCNJ6
SCHEMBL2923247 0.91 MAPK14 (0.39) AXLCSF1RPDGFRABRAFKCNJ6
SCHEMBL3265512 0.90 SRC (0.38) AXLCSF1RPDGFRABRAFKCNJ6
SCHEMBL5063053 0.90 MAPK14 (0.45) AXLCSF1RPDGFRABRAFKDR
SCHEMBL5066522 0.88 AXL (0.41) AXLCSF1RPDGFRABRAFKCNJ6
SCHEMBL2026393 0.88 ABL1 (0.48) AXLCSF1RPDGFRABRAFKCNJ6
SCHEMBL2918935 0.87 AXL (0.52) AXLCSF1RPDGFRABRAFKDR
SCHEMBL2031696 0.87 AXL (0.39) AXLCSF1RPDGFRABRAFKCNJ6
SCHEMBL3140537 0.86 SRC (0.38) AXLCSF1RPDGFRABRAFKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2481736-A1 Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases Deciphera Pharmaceuticals, LLC. (US) 2012-08-01 EP disclosed
US-20080269267-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269267-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES BRAF, RET, KIT AXL 233/4885CSF1R 80/4885PDGFRA 127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.